ASX News

Recommencement of ZIRCON Phase III Trial Recruitment in EU

Melbourne (Australia) – 18th June 2020. Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in Europe

Telix Pharmaceuticals Limited is pleased to announce that the Company’s ZIRCON phase III trial of TLX250-CDx (89Zr-girentuximab) has recommenced patient recruitment in Europe, following a pause to clinical trial activity as a result of the COVID-19 pandemic.

To read full media release please click here.